We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

53 hedge funds and large institutions have $207M invested in Arbutus Biopharma in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $133M → $207M (+$74.3M)

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

6% more funds holding

Funds holding: 50 → 53 (+3)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

7.04% less ownership

Funds ownership: 67.03% → 60% (-7%)

17% less call options, than puts

Call options by funds: $141K | Put options by funds: $169K

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
15
Reduced
15
Closed
8
Calls
$141K
Puts
$169K
Net Calls
-$28K
Net Calls Change
-$322K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$961K
2
SSA
Schonfeld Strategic Advisors
New York
+$535K
3
Morgan Stanley
Morgan Stanley
New York
+$404K
4
RI
RTW Investments
New York
+$241K
5
UBS Group
UBS Group
Switzerland
+$224K

Top Sellers

1
LTFS
Ladenburg Thalmann Financial Services
Florida
-$15.1M
2
SM
Sabby Management
Florida
-$895K
3
Axa
Axa
France
-$881K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$757K
5
KPF
K2 Principal Fund
Ontario, Canada
-$538K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$168K – – –
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$140K -$34K -7,959 -26%
Millennium Management
28
Millennium Management
New York
$124K +$85.7K +20,046 New
Group One Trading
29
Group One Trading
Illinois
$123K +$26.9K +6,281 +46%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$119K – – –
ARTA
31
A.R.T. Advisors
New York
$104K +$72.2K +16,882 New
JP Morgan Chase
32
JP Morgan Chase
New York
$84K +$27.7K +6,485 +97%
State Street
33
State Street
Massachusetts
$83K +$667 +156 +1%
Citigroup
34
Citigroup
New York
$81K +$8.55K +2,000 +18%
TSS
35
Two Sigma Securities
New York
$78K +$53.9K +12,605 New
SIM
36
Spark Investment Management
New York
$71K +$49.6K +11,600 New
Jane Street
37
Jane Street
New York
$68K +$47K +10,983 New
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$64K -$15K -3,500 -25%
Squarepoint
39
Squarepoint
New York
$64K +$44.1K +10,300 New
BlackRock
40
BlackRock
New York
$60K +$41.7K +9,738 New
TRCT
41
Tower Research Capital (TRC)
New York
$51K -$8.31K -1,943 -19%
Wells Fargo
42
Wells Fargo
California
$21K -$1.26K -295 -8%
PCM
43
Prelude Capital Management
New York
$21K +$14.5K +3,400 New
Bank of America
44
Bank of America
North Carolina
$12K – – –
CG
45
Cutler Group
California
$8K -$1.71K -400 -22%
FDCDDQ
46
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.96K – – –
IA
47
IFP Advisors
Florida
$2K – – –
CSS
48
Cubist Systematic Strategies
Connecticut
$2K +$1.28K +300 New
AG
49
Advisor Group
Arizona
$1K -$1.71K -400 -67%
NFG
50
Next Financial Group
Texas
$1K – – –
1
2
3

ABUS Hedge Fund Activity: Q3 2017 in Review

53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2017, worth a combined $207M — up 56% from $133M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABUS positions and 8 closed out — a net gain of 4 holders — while 15 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $961K. The largest seller was Ladenburg Thalmann Financial Services, cutting an estimated $15.1M.

  • 53 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2017, up from 50 in Q2 2017.
  • Funds reported $207M of Arbutus Biopharma stock for Q3 2017, up 56% quarter-over-quarter.
  • 12 funds opened new Arbutus Biopharma positions in Q3 2017 and 8 closed out, a net change of +4 holders.
  • The largest Arbutus Biopharma buyer in Q3 2017 was Point72 Asset Management, an estimated $961K added.
  • The largest Arbutus Biopharma seller in Q3 2017 was Ladenburg Thalmann Financial Services, an estimated $15.1M sold.

Based on aggregated 13F filings for Q3 2017.